TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Three Month Bleeding-Model Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age;~* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;~* Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;~* Have at least 20 gradable teeth;~* Have established gingivitis with 10-70% bleeding sites;~* Agree to return for scheduled visits and follow the study procedures;~* Agree to refrain from use of any non-study oral hygiene products for the duration of the study;~* Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study.~Exclusion Criteria:~* Having taken medications (antibiotic, anti-inflammatory, or anti-coagulant) which could alter gingival bleeding within 4 weeks of the Baseline Visit;~* Having any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;~* Having known hypersensitivity to the test products;~* Having removable oral appliances;~* Having fixed facial or lingual orthodontic appliances;~* Self-reported pregnancy or lactation;~* Having any diseases or condition that might interfere with the safe participation in the study;~* Having an inability to undergo study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Positive Control (Type: ACTIVE_COMPARATOR): 2 brushings per day (AM and PM)
- Negative Control (Type: SHAM_COMPARATOR): 2 brushings per day (AM and PM)
- Experimental Control (Type: EXPERIMENTAL): Brush with Positive control in the morning and negative control in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BGG492 in Patients With Chronic Subjective Tinnitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with THI (Tinnitus Handicap Inventory) severity grade 3, 4 or 5 (moderate, severe or catastrophic), chronic (\> 6 months and \< 36 months) subjective tinnitus~* Willing to abstain from activities that require focused attention, e.g. driving a car or other vehicles, operating machines or engaging in potentially dangerous activities that require focused attention and intact physical balance~* Willing and able to refrain from engaging in activities or work involving loud noise exposure~Exclusion Criteria:~* Patients diagnosed with tinnitus of THI severity grade equal to 2 or 1~* Patients with diagnosis of intermittent or pulsatile tinnitus~* Patients who have tinnitus as a concomitant symptom of a treatable otological disease (such as otitis media, Menière's disease, otosclerosis), neurological tumors or/and have temporo-mandibular joint disorders~* Patients with a history of frequent middle ear infections (\> 3 infections per year during the last 3 years)~* Patients with diagnosed anxiety disorders, depression, schizophrenia or other significant psychiatric diseases requiring current drug treatment or patients who required treatment in the previous 3 months for these diseases.~* Patients with current unilateral or bilateral hearing loss of 75 dB or more in one or more tested frequencies (125 Hz, 250 Hz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, 8 kHz)~* Patients with Vestibular Schwannoma~* Patients with a cochlear implant~* Patients with regular intake of central nervous system acting drugs for the treatment of tinnitus in the previous 6 months prior to initial dosing~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BGG492 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Off-pump Coronary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients for elective offpump coronary artery bypass surgery~Exclusion Criteria:~* A history of bleeding disorders~* Active chronic hepatitis or cirrhosis~* Chronic renal insufficiency (serum creatinine \> 2 mg/dL)~* Preoperative anemia (Hb \< 10 g/dL)~* Previous cardiac surgery~* Myocardial infarction \< 7 days before surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic Acid group (Type: EXPERIMENTAL): None
- Control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol Supplementation, Muscle Strength

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 20 years~* Residence of Delhi~* Commitment for follow-up at 8 weeks, 6 months \& 1 year.~* Consent for 8 weeks of supplementation~Exclusion Criteria:~* Subjects taking drugs, which can affect bone mineral metabolism such as glucocorticoids, antitubercular, antiepileptics, levothyroxine, bisphosphonates~* Chronic renal or liver disorder~* Chronic diarrhea

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A, Choelcalciferol (Type: ACTIVE_COMPARATOR): Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
- B, Lactose (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Electrical Stimulation for Postpartum Neuromuscular Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primiparous (First delivery)~* Women who sustain Obstetric Anal Sphincter Injury (OASIS) during first vaginal delivery~* Between age of 18 - 50 years~* English speaking and reading~Exclusion Criteria:~* Implanted electrical device or cardiac arrhythmia~* Neurological disorder~* Inflammatory bowel disease~* Chronic Steroid Use~* Wound breakdown and infection~* Anticipated geographic relocation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- ApexM Device (Type: EXPERIMENTAL): The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
- Sham Device (Type: SHAM_COMPARATOR): The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Azithromycin and Artesunate in Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* peripheral malaria parasitemia~* signed informed consent~* age 15-49 years~* mother has felt the movements of the foetus (quickening)~* fetal age of at least 14 but not more than 26 completed gestation weeks~* maternal availability for follow-up during the entire period of the study~Exclusion Criteria:~* known maternal tuberculosis, diabetes, kidney disease, or liver disease~* mental disorder that may affect comprehension of the study or success of follow-up~* twin pregnancy~* pregnancy complications evident at enrollment visit (moderate to severe oedema, blood Hb concentration \< 7 g / dl, systolic blood pressure (BP) \> 160 mmHg or diastolic BP \> 100 mmHg)~* prior receipt of azithromycin during current pregnancy~* receipt of any antimalarial within 28 days before enrollment~* known allergy to drugs containing sulfonamides, macrolides or pyrimethamine~* history of anaphylaxis~* history of any serious allergic reaction to any substance, requiring emergency medical care~* history of hepatitis or jaundice~* concurrent participation in any other clinical trial

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* Diagnosis of heterozygous familial hypercholesterolemia~* On a stable dose of an approved statin and lipid regulating medication~* Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* Homozygous familial hypercholesterolemia~* LDL or plasma apheresis~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes, poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
- Placebo QM (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
- Evolocumab Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
- Evolocumab QM (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of exercise induced asthma~* Maximum 4 asthmatic episodes per week requiring use of reliever medication~Exclusion Criteria:~* No previous treatment with inhaled oral corticosteroids during the last month before randomisation~* Suspected poor capability to follow instructions, ie to exercise 3-4 times a week

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): budesonide 400yg + terbutaline 0.4 mg as-needed
- B (Type: ACTIVE_COMPARATOR): placebo + terbutaline 0.4 mg as-needed
- C (Type: ACTIVE_COMPARATOR): placebo + budesonide/formoterol 160/4.5 yg as-needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of epilepsy with uncontrolled partial onset seizures, whether or not secondarily generalized, and the diagnosis was \>= 6 months before the Selection Visit~* epilepsy was classifiable according to the ILAE Classification~* \>= 4 partial onset seizures during the 4 weeks preceding the Selection Visit and were required to have \>= 4 partial onset seizures during each 4-week interval of the Baseline Period to qualify for randomization~* unsatisfactory current AED treatment in terms of efficacy and/or safety~* stable AED treatment consisting of no more than two AEDs~Exclusion Criteria:~* treatable seizure etiology~* epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases~* history of status epilepticus which required hospitalization during 3 months prior to the Selection Visit~* history of or the presence of pseudo seizures~* current diagnosis of Lennox-Gastaut syndrome

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (LEV) (Type: EXPERIMENTAL): LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received Placebo matching to LEV treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* CHC infection;~* liver biopsy (in \<24 calendar months of first dose), with results consistent with CHC infection;~* use of 2 forms of contraception during study and 6 months after the study in both men and women;~* Lack of response to previous treatment with peginterferon alfa-2b (12KD)/ribavirin combination therapy given for \>=12 weeks.~Exclusion Criteria:~* women who are pregnant or breastfeeding;~* male partners of women who are pregnant;~* conditions associated with decompensated liver disease;~* other forms of liver disease, including liver cancer;~* human immunodeficiency virus infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically diagnosed cancer with fever and chemotherapy-induced neutropenia (absolute neutrophil count no greater than 500/mm3)~  * Acute onset of fever of at least 38.8 degrees Celsius that is not related to the administration of blood products or pyrogenic substances~* No acute myelogenous leukemia~* No myelodysplastic syndrome~* No solid tumor with bone marrow involvement~PATIENT CHARACTERISTICS:~Age:~* 21 and under~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Creatinine less than 1.5 times upper limit of normal~Renal:~* Not specified~Other:~* No patients in septic shock~* No prolonged fever of unknown origin~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)~* See Chemotherapy~Chemotherapy:~* No prior or concurrent myeloablative chemoradiotherapy with bone marrow or peripheral stem cell rescue~Endocrine therapy:~* Not specified~Radiotherapy:~* See Chemotherapy~* No prior radiotherapy to marrow reserves (i.e., craniospinal and/or pelvic irradiation)~Surgery:~* Not specified~Other:~* At least 7 days since prior IV antibiotics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Assessment of a HYDRAGLYDE® Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign informed consent document;~* Vision correctable to 0.1 (LogMAR) or better in each eye at distance with habitual lenses;~* Manifest cylinder (at screening) less than or equal to 0.75 diopter (D) in each eye and spectacle add \<+0.50 D in each eye;~* Current full-time wearer of spherical samfilcon A, comfilcon A, senofilcon C monthly or senofilcon A 2-week replacement lens within the power range of lens powers available;~* Current user of an MPS (excluding OFPM) to care for lenses;~* Willing to answer text messages on a daily basis during the study;~* Willing to discontinue artificial tears during the study and rewetting drops on the days of study visits;~* Use of digital devices (eg, smart phone, tablet, laptop or desktop computer) for 20 consecutive minutes at least twice a week and willing to continue for the duration of the study;~* Other protocol specific inclusion criteria may apply.~Exclusion Criteria:~* Habitual lens wear in an extended wear modality (routinely sleeping in lenses overnight for 1 or more nights per week);~* Any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear;~* History of herpetic keratitis, corneal surgery or irregular cornea;~* Prior refractive surgery;~* Any use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator;~* Currently using or have not discontinued Restasis®, Xiidra™ and/or topical steroids within the past 7 days;~* Use of mechanical eyelid therapy or eyelid scrubs within 14 days before Visit 1 and not willing to discontinue during the study;~* Monocular (only 1 eye with functional vision) or fit with only 1 lens;~* Known pregnancy or lactating;~* Other protocol specific exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AOHG (Type: EXPERIMENTAL): Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
- Habitual (Type: ACTIVE_COMPARATOR): Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete